Immunoprecise Non Current Liabilities Total vs Net Debt Analysis

IPA Stock

USD 1.28 0.09 6.57%

Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Non Current Liabilities Total and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Non Current Liabilities Total vs Net Debt

Non Current Liabilities Total vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Non Current Liabilities Total account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Immunoprecise Antibodies' Non Current Liabilities Total and Net Debt is -0.07. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Net Debt in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Non Current Liabilities Total and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Immunoprecise Antibodies are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Non Current Liabilities Total i.e., Immunoprecise Antibodies' Non Current Liabilities Total and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Current Liabilities Total

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.The current year's Selling General Administrative is expected to grow to about 23.9 M, whereas Tax Provision is projected to grow to (1 M).

	2021	2022	2023	2024 (projected)
Gross Profit	11.0M	11.6M	13.3M	14.0M
Total Revenue	19.4M	20.7M	23.8M	25.0M

Gross Profit Total Revenue

Immunoprecise Antibodies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Non Currrent Assets Other	Short Long Term Debt Total	Property Plant And Equipment Gross	Short Term Debt	Inventory	Current Deferred Revenue	Intangible Assets
Total Assets		0.32	0.84	0.99	0.87	-0.47	-0.88	0.98	0.68	0.95	0.67	0.93	0.96	-0.26	0.99	-0.2	0.94	0.81	0.9	-0.32	0.76	0.89	0.53	0.89	0.74	0.93
Other Current Liab	0.32		0.75	0.27	0.09	-0.21	-0.07	0.44	0.29	0.26	0.28	0.46	0.37	-0.25	0.19	-0.53	0.46	0.34	0.25	-0.05	0.23	0.06	0.8	0.45	0.63	0.17
Total Current Liabilities	0.84	0.75		0.81	0.64	-0.41	-0.64	0.89	0.59	0.78	0.58	0.88	0.86	-0.33	0.76	-0.43	0.88	0.71	0.72	-0.28	0.65	0.64	0.86	0.86	0.9	0.74
Total Stockholder Equity	0.99	0.27	0.81		0.84	-0.54	-0.86	0.97	0.73	0.92	0.72	0.9	0.93	-0.24	0.99	-0.17	0.9	0.85	0.86	-0.33	0.72	0.87	0.49	0.87	0.72	0.91
Property Plant And Equipment Net	0.87	0.09	0.64	0.84		-0.06	-0.91	0.8	0.31	0.94	0.3	0.88	0.93	-0.17	0.89	-0.09	0.9	0.49	0.95	-0.29	0.89	0.99	0.33	0.86	0.59	0.91
Net Debt	-0.47	-0.21	-0.41	-0.54	-0.06		0.17	-0.48	-0.96	-0.18	-0.97	-0.33	-0.27	0.12	-0.47	0.15	-0.21	-0.89	-0.07	0.19	0.01	-0.08	-0.25	-0.24	-0.42	-0.18
Retained Earnings	-0.88	-0.07	-0.64	-0.86	-0.91	0.17		-0.82	-0.39	-0.92	-0.38	-0.81	-0.89	0.3	-0.9	-0.16	-0.86	-0.55	-0.9	0.5	-0.71	-0.94	-0.4	-0.83	-0.57	-0.91
Accounts Payable	0.98	0.44	0.89	0.97	0.8	-0.48	-0.82		0.68	0.93	0.67	0.92	0.94	-0.32	0.95	-0.27	0.95	0.8	0.88	-0.24	0.74	0.83	0.57	0.87	0.77	0.9
Cash	0.68	0.29	0.59	0.73	0.31	-0.96	-0.39	0.68		0.41	1.0	0.57	0.51	-0.19	0.67	-0.2	0.45	0.98	0.32	-0.25	0.23	0.32	0.37	0.46	0.59	0.4
Non Current Assets Total	0.95	0.26	0.78	0.92	0.94	-0.18	-0.92	0.93	0.41		0.4	0.9	0.96	-0.25	0.94	-0.15	0.97	0.58	0.98	-0.28	0.83	0.97	0.48	0.9	0.66	0.98
Cash And Short Term Investments	0.67	0.28	0.58	0.72	0.3	-0.97	-0.38	0.67	1.0	0.4		0.56	0.5	-0.15	0.67	-0.2	0.44	0.98	0.31	-0.25	0.22	0.31	0.36	0.45	0.58	0.39
Net Receivables	0.93	0.46	0.88	0.9	0.88	-0.33	-0.81	0.92	0.57	0.9	0.56		0.97	-0.33	0.91	-0.34	0.95	0.72	0.9	-0.24	0.87	0.85	0.6	0.88	0.86	0.84
Common Stock Shares Outstanding	0.96	0.37	0.86	0.93	0.93	-0.27	-0.89	0.94	0.51	0.96	0.5	0.97		-0.32	0.94	-0.27	0.98	0.68	0.95	-0.27	0.88	0.93	0.57	0.94	0.79	0.93
Short Term Investments	-0.26	-0.25	-0.33	-0.24	-0.17	0.12	0.3	-0.32	-0.19	-0.25	-0.15	-0.33	-0.32		-0.25	0.02	-0.31	-0.2	-0.26	-0.1	-0.33	-0.2	-0.24	-0.29	-0.36	-0.25
Other Current Assets	0.99	0.19	0.76	0.99	0.89	-0.47	-0.9	0.95	0.67	0.94	0.67	0.91	0.94	-0.25		-0.12	0.91	0.8	0.89	-0.34	0.76	0.91	0.43	0.85	0.7	0.92
Other Stockholder Equity	-0.2	-0.53	-0.43	-0.17	-0.09	0.15	-0.16	-0.27	-0.2	-0.15	-0.2	-0.34	-0.27	0.02	-0.12		-0.28	-0.24	-0.16	-0.62	-0.46	-0.05	-0.3	-0.25	-0.51	-0.15
Total Liab	0.94	0.46	0.88	0.9	0.9	-0.21	-0.86	0.95	0.45	0.97	0.44	0.95	0.98	-0.31	0.91	-0.28		0.62	0.96	-0.24	0.85	0.91	0.6	0.92	0.77	0.93
Total Current Assets	0.81	0.34	0.71	0.85	0.49	-0.89	-0.55	0.8	0.98	0.58	0.98	0.72	0.68	-0.2	0.8	-0.24	0.62		0.5	-0.29	0.41	0.5	0.46	0.62	0.69	0.56
Non Current Liabilities Total	0.9	0.25	0.72	0.86	0.95	-0.07	-0.9	0.88	0.32	0.98	0.31	0.9	0.95	-0.26	0.89	-0.16	0.96	0.5		-0.2	0.88	0.96	0.39	0.87	0.61	0.94
Non Currrent Assets Other	-0.32	-0.05	-0.28	-0.33	-0.29	0.19	0.5	-0.24	-0.25	-0.28	-0.25	-0.24	-0.27	-0.1	-0.34	-0.62	-0.24	-0.29	-0.2		0.1	-0.3	-0.46	-0.37	-0.18	-0.26
Short Long Term Debt Total	0.76	0.23	0.65	0.72	0.89	0.01	-0.71	0.74	0.23	0.83	0.22	0.87	0.88	-0.33	0.76	-0.46	0.85	0.41	0.88	0.1		0.86	0.33	0.79	0.68	0.81
Property Plant And Equipment Gross	0.89	0.06	0.64	0.87	0.99	-0.08	-0.94	0.83	0.32	0.97	0.31	0.85	0.93	-0.2	0.91	-0.05	0.91	0.5	0.96	-0.3	0.86		0.33	0.86	0.56	0.96
Short Term Debt	0.53	0.8	0.86	0.49	0.33	-0.25	-0.4	0.57	0.37	0.48	0.36	0.6	0.57	-0.24	0.43	-0.3	0.6	0.46	0.39	-0.46	0.33	0.33		0.67	0.79	0.45
Inventory	0.89	0.45	0.86	0.87	0.86	-0.24	-0.83	0.87	0.46	0.9	0.45	0.88	0.94	-0.29	0.85	-0.25	0.92	0.62	0.87	-0.37	0.79	0.86	0.67		0.73	0.88
Current Deferred Revenue	0.74	0.63	0.9	0.72	0.59	-0.42	-0.57	0.77	0.59	0.66	0.58	0.86	0.79	-0.36	0.7	-0.51	0.77	0.69	0.61	-0.18	0.68	0.56	0.79	0.73		0.63
Intangible Assets	0.93	0.17	0.74	0.91	0.91	-0.18	-0.91	0.9	0.4	0.98	0.39	0.84	0.93	-0.25	0.92	-0.15	0.93	0.56	0.94	-0.26	0.81	0.96	0.45	0.88	0.63

Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.3M	67.0M	93.5M	77.8M	89.5M	94.0M
Other Current Liab	1.8M	964K	1.3M	441K	507.2K	558.1K
Total Current Liabilities	7.9M	6.1M	9.3M	5.9M	6.8M	7.1M
Total Stockholder Equity	15.1M	56.9M	75.3M	57.8M	66.5M	69.8M
Property Plant And Equipment Net	3.2M	4.1M	3.7M	10.7M	12.3M	12.9M
Net Debt	1.9M	(38.3M)	(27.4M)	(1.0M)	(911.7K)	(957.3K)
Retained Earnings	(22.5M)	(29.8M)	(46.5M)	(73.1M)	(65.8M)	(62.5M)
Accounts Payable	1.8M	3.0M	4.8M	3.4M	3.9M	4.1M
Cash	2.6M	41.8M	30.0M	8.3M	9.5M	10.0M
Non Current Assets Total	19.6M	18.1M	56.0M	61.0M	70.2M	73.7M
Cash And Short Term Investments	2.6M	41.8M	30.0M	8.3M	9.5M	10.0M
Net Receivables	3.7M	4.1M	3.4M	4.4M	5.1M	5.3M
Common Stock Shares Outstanding	13.6M	16.5M	19.7M	24.9M	28.6M	30.1M
Liabilities And Stockholders Equity	27.3M	67.0M	93.5M	77.8M	89.5M	94.0M
Other Current Assets	614.0K	2.3M	2.8M	2.6M	3.0M	3.1M
Other Stockholder Equity	3.5M	6.6M	7.3M	10.8M	9.7M	9.2M
Total Liab	12.2M	10.0M	18.2M	20.0M	23.0M	24.2M
Total Current Assets	7.7M	48.9M	37.5M	16.8M	19.3M	20.3M
Non Current Liabilities Total	4.2M	4.0M	8.9M	14.1M	16.2M	17.0M
Non Currrent Assets Other	85.1K	79K	82K	86K	77.4K	73.5K
Short Long Term Debt Total	4.5M	3.5M	2.5M	7.3M	8.4M	8.8M
Property Plant And Equipment Gross	3.1M	4.1M	9.4M	17.1M	19.6M	20.6M
Accumulated Other Comprehensive Income	(300.2K)	(687K)	(2.5M)	2.6M	2.4M	2.5M
Short Term Debt	2.9M	986K	2.2M	1.1M	1.3M	888.8K
Inventory	818.6K	1.2M	1.6M	2.1M	2.4M	2.5M
Current Deferred Revenue	1.5M	1.1M	1.0M	977K	1.1M	567.8K
Intangible Assets	8.3M	6.1M	32.4M	30.9M	35.6M	37.3M
Common Stock	34.1M	80.1M	114.6M	117.5M	135.1M	141.8M
Net Tangible Assets	(1.0M)	43.1M	23.2M	7.7M	8.9M	12.5M
Net Invested Capital	17.7M	58.5M	76.6M	57.8M	66.5M	39.4M
Net Working Capital	(230.3K)	42.8M	28.2M	10.9M	12.5M	13.7M
Property Plant Equipment	3.1M	4.0M	3.3M	10.4M	12.0M	12.5M
Other Liab	2.6M	1.5M	8.6M	7.9M	9.1M	5.1M
Other Assets	287.6K	163K	476K	437K	393.3K	373.6K
Good Will	7.9M	7.8M	19.7M	19.2M	22.0M	12.4M
Capital Lease Obligations	1.9M	1.9M	1.2M	7.3M	8.4M	8.8M
Long Term Investments	118.9K	111K	142K	115K	132.3K	122.4K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:

How To Invest In Immunoprecise

Details

Is Immunoprecise Stock a good investment?

Details

What is Immunoprecise Antibodies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.

	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.42)

Revenue Per Share

0.939

Quarterly Revenue Growth

0.203

Return On Assets

(0.11)

Return On Equity

(0.26)

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunoprecise Non Current Liabilities Total vs Net Debt Analysis

Non Current Liabilities Total vs Net Debt

Non Current Liabilities Total vs Net Debt Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Net Debt

Immunoprecise Antibodies fundamental ratios Correlations

Immunoprecise Antibodies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunoprecise Antibodies fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Immunoprecise Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Accounts Payable	+ 0.98	Total Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.96	Net Debt
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Non Current Assets Total	- 0.92	Retained Earnings
Intangible Assets	- 0.91	Retained Earnings
Retained Earnings	- 0.91	Property Plant And Equipment Net